SYBX

Synlogic Inc

SYBX, USA

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.

https://www.synlogictx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SYBX
stock
SYBX

12 Health Care Stocks Moving In Thursday's Intraday Session Benzinga

Read more →
SYBX
stock
SYBX

Can SYRE stock surprise with earnings upside - Weekly Trend Summary & Technical Confirmation Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$1

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.32

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-22.29 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.90 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Medium

0.60

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 61.33% of the total shares of Synlogic Inc

1.

Cable Car Capital LLC

(28.3122%)

since

2025/06/30

2.

NEA Management Company, LLC

(24.9833%)

since

2025/06/30

3.

Vanguard Group Inc

(1.5643%)

since

2025/06/30

4.

FMR Inc

(1.4189%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(1.1665%)

since

2025/07/31

6.

Fidelity VIP Growth Initial

(0.6568%)

since

2025/07/31

7.

Geode Capital Management, LLC

(0.5662%)

since

2025/06/30

8.

Fidelity Advisor Equity Growth I

(0.3685%)

since

2025/07/31

9.

Fidelity Extended Market Index

(0.3156%)

since

2025/07/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2759%)

since

2025/07/31

11.

Fidelity Growth Discovery

(0.2501%)

since

2025/07/31

12.

Renaissance Technologies Corp

(0.2035%)

since

2025/06/30

13.

Fiduciary Trust Co

(0.1911%)

since

2025/06/30

14.

Ikarian Capital, LLC

(0.1746%)

since

2025/06/30

15.

BlackRock Inc

(0.1689%)

since

2025/06/30

16.

Fidelity Advisor Series Equity Gr

(0.091%)

since

2025/07/31

17.

Susquehanna International Group, LLP

(0.087%)

since

2025/06/30

18.

State Street Corp

(0.087%)

since

2025/06/30

19.

Fidelity Series Total Market Index

(0.0815%)

since

2025/07/31

20.

Fidelity Nasdaq Composite Index

(0.0773%)

since

2025/07/31

21.

Pacific Select Large-Cap Growth I

(0.0498%)

since

2025/08/31

22.

Spartan Extended Market Index Pool F

(0.0473%)

since

2025/07/31

23.

Fidelity Total Market Index

(0.0327%)

since

2025/07/31

24.

NT Ext Equity Mkt Idx Fd - NL

(0.0286%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0222%)

since

2025/06/30

26.

NT Ext Equity Mkt Idx Fd - L

(0.0219%)

since

2025/06/30

27.

Northern Trust Extended Eq Market Idx

(0.0219%)

since

2025/06/30

28.

Extended Equity Market Fund K

(0.0185%)

since

2025/06/30

29.

State St US Extended Mkt Indx NL Cl C

(0.018%)

since

2025/08/31

30.

Spartan Total Market Index Pool G

(0.0117%)

since

2025/07/31

31.

Morgan Stanley - Brokerage Accounts

(0.0096%)

since

2025/06/30

32.

Vanguard U.S. Eq Idx £ Acc

(0.0092%)

since

2025/07/31

33.

SBI Securities Co Ltd

(0.0009%)

since

2025/06/30

34.

Bank of America Corp

(0.0006%)

since

2025/06/30

35.

BNP Paribas Arbitrage, SA

(0.0002%)

since

2025/06/30

36.

JPMorgan Chase & Co

(0%)

since

2025/06/30

37.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.1868

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(2)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.